Background/Aims: With advanced anticoagulation, many institutions operate continuous renal replacement therapy (CRRT) circuits longer than manufacturers’ recommendations. This extended use may change hemodiafilter performance and clearance properties. However, hemodiafilter performance over time has not been assessed. We investigated solute clearance over time in modeled CRRT. Methods: In vitro continuous hemofiltration (CH) and continuous hemodialysis (CD) were operated for 48 h using AN69 polyacrylonitrile, cellulose triacetate, F70 polysulfone, and Optiflux F160NR polysulfone hemodiafilters with citrated bovine blood. Urea, creatinine, gentamicin, vancomycin, and albumin clearances were assessed in CH (ultrafiltration rates = 1 and 3 l/h). Clearances of urea, creatinine, gentamicin, and albumin, were assessed in CD with dialysate flow rate of 2 l/h. Results: Solute CH clearances were significantly higher at 3 l/h. Only creatinine and gentamicin clearances were affected by time. Creatinine CD clearance significantly declined at 48 h for all hemodiafilters, especially polysulfone hemodiafilters. Conclusions: CRRT duration affects solute transmembrane clearance. Clinicians should consider hemodiafilter age when assessing hemodialysis dose or drug clearance.

Keywords:
Clearance, Continuous renal replacement therapy, Hemodialysis, Hemofiltration
1.
Clark WR, Mueller BA, Alaka KJ, Macias WL: A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994;4:1413–1420.
2.
Mueller BA, Pasko DA, Sowinski KM: Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003;27:808–814.
3.
Stevenson JM, Patel JH, Churchwell MD, Vilay AM, DePestel DD, Sörgel F, Kinzig M, Jakob V, Mueller BA: Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008:1027–1034.
4.
Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006;24:548–554.
5.
Schetz M: Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 2007;13:645–651.
6.
Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE (eds): Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, ed 5. Philadelphia, American College of Physicians, 2007.
7.
Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA: Trace element removal during in vitro and in vivo continuous haemodialysis. Nephrol Dial Transplant 2008;22:2970–2977.
8.
Macias WL, Alaka KJ, Murphy MH, Miller ME, Clark WR, Mueller BA: Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure. J Parenteral Enteral Nutr 1996;20:56–62.
9.
Maxvold NJ, Smoyer WE, Custer JR, Bunchman TE: Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Crit Care Med 2000;28:1161–1165.
10.
Rogiers P: Hemofiltration treatment of sepsis: is it time for controlled trials? Kidney Int 1999;72:S99–S103.
11.
Bottoms G, Fessler J, Murphey E, Johnson M, Latshaw H, Mueller B, Clark W, Macias W: Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 1996;5:149–154.
12.
Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;4:522–526.
13.
De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lamiere NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846–853.
14.
Tian Q, Gomersall CD, Ip M, Tan TE, Joynt GM, Choi G: Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agent Chemother 2008;53:1009–1013.
15.
Choi G, Gomersall CD, Lipman J, Wong A, Joynt GM, Leung P, Ramsay SJ, Ho OM: The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration. An in vitro study of levofloxacin. Int J Antimicrob Agents 2004;24:468–472.
16.
Tian Q, Gomersall CD, Leung PN, Choi G, Joynt GM, Tan PE, Wong A: The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs 2008;32:81–84.
17.
Clark WR, Macias WL, Molitoris BA, Wang NH: Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int 1995;48:481–485.
18.
Martin PY, Chevrolet JC, Suter P, Favre H: Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 1994;24:806–812.
19.
Swartz R, Pasko DA, O’Toole J, Starmann B: Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004;61:134–143.
20.
Sigler MH, Manns M: Membranes and devices used in continuous renal replacement. Semin Dial 1996;9:98–106.
21.
Marshall MR: Current status of dosing and quantification of acute renal replacement therapy. 2. Dosing paradigms and clinical implementation. Nephrol Dial Transplant 2006;11:181–191.
22.
Mehta RL, Martin RK: Initiating and implementing a continuous renal replacement therapy program. Semin Dial 1996;9:80–87.
23.
Wei J, Granado RC, Malhotra R, Macedo E, Luo Y, Soroko S, Mehta RL: The impact of down-time and filter efficacy on delivered dose of continuous renal replacement therapy. J Am Soc Nephrol 2010;21:38A.
24.
Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellow R: Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intens Care Med 2002;28:1664–1667.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.